Olli Kärkkäinen
@ollikarkkainen.bsky.social
790 followers
760 following
59 posts
Senior researcher in drug toxicology at University of Eastern Finland and co-founder and CEO of Afekta Technologies Ltd. Metabolomics, biomarkers, alcohol, drugs, nutrition, disease progression, treatment responses. https://orcid.org/0000-0003-0825-4956
Posts
Media
Videos
Starter Packs
Check out this preprint of the first article for my PhD thesis!
www.biorxiv.org/content/10.1...
We've leveraged methods developed for multi-omics to investigate a holo-omic system (🐷🦠), and predicted host-microbiome interactions between important features for observed cross-omic data patterns 🔍📊
www.biorxiv.org/content/10.1...
We've leveraged methods developed for multi-omics to investigate a holo-omic system (🐷🦠), and predicted host-microbiome interactions between important features for observed cross-omic data patterns 🔍📊
Reposted by Olli Kärkkäinen
Reposted by Olli Kärkkäinen
Reposted by Olli Kärkkäinen
Reposted by Olli Kärkkäinen
Reposted by Olli Kärkkäinen
Reposted by Olli Kärkkäinen
Leah Mayo
@mayoonthebrain.bsky.social
· May 17
The efficacy of elevating anandamide via inhibition of fatty acid amide hydrolase (FAAH) combined with internet-delivered cognitive behavioral therapy in the treatment of post-traumatic stress disorde...
Neuropsychopharmacology - The efficacy of elevating anandamide via inhibition of fatty acid amide hydrolase (FAAH) combined with internet-delivered cognitive behavioral therapy in the treatment of...
www.nature.com
Reposted by Olli Kärkkäinen
Reposted by Olli Kärkkäinen
Reposted by Olli Kärkkäinen